Pacific Endoscopic Imaging Pty Ltd
Pacific Endoscopic Imaging P/L is an Australian company started by Clemens van Der Weegen an Australian entrepreneur and physical biological researcher, who over 20 years of R&D, invented and developed new technology primarily to conduct more comfortable Pap and HPV testing for women. The invention and development led to the Veda-Scope that is patented and TGA approved. This technology provides a camera view and can take images to provide greater and more accurate information for early detection of cervical and vaginal cancers.    Clemens has recently updated the technology further (Veda-Scope MKII) to provide even greater comfort to women undergoing these tests together with greater ease of use by medical practitioners who perform the test.  The Veda-Scope has had two extensive clinical trials conducted on over 330 women with 94% of those women preferring the Veda-Scope method over the traditional method. Its resounding positive feedback that has been documented and published by the clinicians involved.  This device will allow all women to have a more comfortable and thorough procedure for early detection cervical and vaginal cancer.


Board of Directors
Chairman/Executive Director/Inventor/Founder
Clemens van Der Weegen
Independent Director – Professor Michael Bennett
Emeritus Professor
Independent Director
Mark A Guest CPA


Veda Scope MKII
Veda-Scope MKII is a new technological device developed to replace the current “Duck Bill” method of taking Pap/HPV tests.  The Veda-Scope device provides the medical professional with the ability to adjust and view directly through the camera with on screen live images that can be magnified as the test is being performed.  The images can then be stored for further analysis and review, or to provide historical records for comparison over time.  It provides full digital capability for Tele-Health via Wi-Fi for easy transfer of data and imagery to allow for a specialist’s analysis and opinion.  The current Duck Bill method does not provide a clear or detailed view of the cervix or vaginal walls and so is substantially less effective in detecting potential precancerous changes to the cervix or vaginal walls.


Executive Team
Chief Executive Officer
Patricia Nance
Chief Financial Officer
Sean Bundy
Business Development
Leo Borovilas
Marketing Manager
Luke Hankinson